Genmab A/S is an international biotechnology company focused on the research, development, and commercialization of innovative antibody-based therapies. Its primary mission is to transform the treatme... Genmab A/S is an international biotechnology company focused on the research, development, and commercialization of innovative antibody-based therapies. Its primary mission is to transform the treatment landscape for cancer and other serious diseases through cutting-edge antibody technologies. Since its founding in 1999 and headquartered in Copenhagen, Genmab has established itself as a leader in the biotechnology industry by engineering and advancing novel antibody therapeutics designed to target complex diseases more effectively. The company’s portfolio spans proprietary products as well as collaborations with major pharmaceutical partners, contributing to a robust pipeline of medicines in oncology and related fields. Genmab’s antibody platforms and scientific expertise position it as a key driver of progress in the healthcare and biopharmaceutical sectors, playing a significant role in delivering next-generation therapies to patients around the world.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Waste Management data disclosed by Genmab

We reviewed Genmab's website and available disclosure materials for the 2023 reporting period and did not identify any reported Waste Management data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review Genmab's data?

Start your 30-day free trial to request a data review for Genmab.

Start Free Trial

Legal Center Contact Us